Medtronic Plc's (NYSE: MDT) reported Q2 FY24 sales of $7.984 billion, up 5.3% Y/Y as reported and 5% organic, slightly beating the consensus of $7.92 billion.
"We're delivering a track record of durable, mid-single digit revenue growth. The underlying fundamentals are strong, and our solid results were broad-based across our businesses and geographies," said Geoff Martha, Medtronic chairman and chief executive officer.
Medtronic's heart device unit sales increased 5.9% Y/Y (+4.8% organic) to $2.92 billion. Spine and neurosurgery product segment sales increased 4.7% Y/Y (+4.2%)